Overview

This trial is active, not recruiting.

Condition contraception
Treatment ess505 (bay1454033)
Sponsor Bayer
Start date September 2013
End date September 2015
Trial size 612 participants
Trial identifier NCT01948882, 16973

Summary

The Essure System is indicated for women who desire non-incisional permanent birth control (female sterilization) by occlusion of the fallopian tubes. The objective of the study is to evaluate the safety and effectiveness of the Essure System (Model ESS505) for permanent birth control in preventing pregnancy. The Essure ESS505 System includes a design modification that will be studied to determine if it provides immediate birth control, thereby removing the three months waiting period required for the commercially available Essure System Model 305 to be effective.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose prevention
Arm
(Experimental)
All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
ess505 (bay1454033)

Primary Outcomes

Measure
Number of confirmed pregnancies at 1 year among subjects told to rely on ESS505 for contraception
time frame: 1 year
Reliance rate, defined as number of subjects told to rely on ESS505 after the Essure confirmation test divided by the number of subjects who had insert placement attempted
time frame: 3 months

Secondary Outcomes

Measure
Number of confirmed pregnancies at 10 years among subjects told to rely on ESS505 for contraception
time frame: 10 years
Safety of the ESS505 placement procedure defined as number of subjects who experience an AE assessed as related to the ESS505 placement procedure divided by the number of subjects in who at least one ESS505 was introduced into the fallopian tube
time frame: On day of placement procedure
Safety of subsequent wearing of the insert defined as number of subjects who experience an AE assessed as related to wearing of ESS505 divided by the number of subjects in whom the presence of an AE could be assessed
time frame: Up to 10 years

Eligibility Criteria

Female participants from 21 years up to 44 years old.

Inclusion Criteria: - Female, 21 to 44 years of age, inclusive - Body weight within range of 90-300 lbs (40 - 136 kg) - Sexually active (minimum of 4 coital acts per cycle) - Willing to accept the risk of pregnancy while relying solely on the inserts for contraception - Medical history indicates bilateral viable and patent fallopian tubes - Agrees to fulfill local requirements for counseling and consent to contraception and sterilization, including any required waiting periods Exclusion Criteria: - Post-menopausal woman - Suspected or confirmed pregnancy - Post-partum or pregnancy termination ≤6 weeks of scheduled insert placement - Past fallopian tube sterilization procedure and/or total or partial salpingectomies - Diagnosis of any of the following: tubal, endometrial, or myometrial pathology (which may prevent fallopian tube ostia access), proximal tubal occlusion in either fallopian tube, unicornuate uterus, active or recent upper or lower pelvic infection, gynecologic malignancy - Currently taking corticosteroids - Known allergy to all contrast media available for use in hysterosalpingogram - Scheduled to undergo concomitant intrauterine procedures at the time of insert placement (intrauterine device removal is not considered a concomitant procedure) - Any general health condition or systemic disease that may represent, in the opinion of the physician, a potential increased risk associated with device use or pregnancy

Additional Information

Official title A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Bayer.